We are live on ! Find out more
CTNM

Contineum Therapeutics
CTNM

90 hedge funds and large institutions have $399M invested in Contineum Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 11

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

18% more capital invested

Capital invested by funds: $338M → $399M (+$60.7M)

13% more funds holding

Funds holding: 80 → 90 (+10)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

34.64% less ownership

Funds ownership: 128.15% → 93.52% (-35%)

Holders
90
Holders Change
+10
Holders Change %
+12.5%
% of All Funds
1.11%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
22
Increased
29
Reduced
21
Closed
11
Calls
$148K
Puts
–
Net Calls
+$148K
Net Calls Change
+$191K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$9.45M
2
IC
Ikarian Capital
Texas
+$7.04M
3
Citadel Advisors
Citadel Advisors
Florida
+$4.7M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.83M
5
LP
Longaeva Partners
Illinois
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$11.9M
2
CC
Commodore Capital
New York
-$9.33M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.04M
4
PA
Perceptive Advisors
New York
-$2.8M
5
Ameriprise
Ameriprise
Minnesota
-$2.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$3.69M +$914K +68,169 +32%
ACM
27
ADAR1 Capital Management
Texas
$3.61M -$30.9K -2,300 -0.8%
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$3.04M +$2.54M +189,456 +440%
UBS Group
29
UBS Group
Switzerland
$3.01M +$416K +31,020 +16%
Marshall Wace
30
Marshall Wace
United Kingdom
$2.96M +$610K +45,498 +25%
BFM
31
Boothbay Fund Management
New York
$2.9M +$2.01M +149,835 +207%
SFM
32
Sphera Funds Management
Israel
$2.27M – – –
VFT
33
Vanguard Fiduciary Trust
Pennsylvania
$2.01M +$2.06M +153,924 New
CC
34
Casdin Capital
New York
$1.94M – – –
EP
35
Eversept Partners
New York
$1.91M +$120K +8,918 +6%
Charles Schwab
36
Charles Schwab
California
$1.88M +$455K +33,948 +31%
II
37
Ishara Investments
California
$1.85M +$1.9M +142,000 New
Jane Street
38
Jane Street
New York
$1.4M +$1.07M +79,435 +284%
State Street
39
State Street
Massachusetts
$1.32M +$226K +16,850 +20%
VA
40
Verdad Advisers
Massachusetts
$1.12M +$1.15M +86,032 New
Point72 Asset Management
41
Point72 Asset Management
Connecticut
$1.11M -$9.04M -674,336 -89%
Morgan Stanley
42
Morgan Stanley
New York
$925K -$717K -53,485 -43%
Renaissance Technologies
43
Renaissance Technologies
New York
$906K +$165K +12,300 +22%
Northern Trust
44
Northern Trust
Illinois
$861K +$162K +12,052 +22%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$782K +$804K +59,946 New
Squarepoint
46
Squarepoint
New York
$782K +$803K +59,844 New
Wellington Management Group
47
Wellington Management Group
Massachusetts
$726K +$746K +55,609 New
6CM
48
683 Capital Management
New York
$718K -$489K -36,442 -40%
Acadian Asset Management
49
Acadian Asset Management
Massachusetts
$703K -$143K -10,637 -16%
SWA
50
Strategies Wealth Advisors
Michigan
$653K – – –
1
2
3 4 5

CTNM Hedge Fund Activity: Q1 2026 in Review

90 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q1 2026, worth a combined $399M — up 18% from $338M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CTNM positions and 11 closed out — a net gain of 11 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Millennium Management, adding an estimated $9.45M. The largest seller was RA Capital Management, cutting an estimated $11.9M.

  • 90 institutional investors held Contineum Therapeutics (CTNM) as of Q1 2026, up from 80 in Q4 2025.
  • Funds reported $399M of Contineum Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
  • 22 funds opened new Contineum Therapeutics positions in Q1 2026 and 11 closed out, a net change of +11 holders.
  • The largest Contineum Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $9.45M added.
  • The largest Contineum Therapeutics seller in Q1 2026 was RA Capital Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q1 2026.